Surrozen, Inc.
SRZN
Rank in Stocks
#13647
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates... Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchsβ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-Γ, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Share Price
$31.61
Last synced: 2026-11-13
Market Cap
$372.18M
Change (1 day)
-0.19%
Change (1 year)
143.53%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Surrozen, Inc. (SRZN)
Category
Healthcare
Operating Margin for Surrozen, Inc. (SRZN)
Operating Margin as of November 2026 TTM: -385.28%
According to Surrozen, Inc.'s latest financial reports, its current operating margin (TTM) is -385.28%. At the end of 2025 the company had an operating margin of -1,210.58%.
Operating Margin history for Surrozen, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -385.28% | -68.17% |
| 2025 | -1,210.58% | 405.06% |
| 2024 | -239.69% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -354.71% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -99.53% |
US
|
|
| 38.59% | -100.10% |
US
|
|
| -149.01% | -99.61% |
US
|
|
| 25.57% | -100.07% |
AU
|
|
| 31.23% | -100.08% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Surrozen, Inc.'s operating margin
What is Surrozen, Inc.'s operating margin?
Surrozen, Inc.'s operating margin is -385.28%, as of Nov 2026.
What was Surrozen, Inc.'s operating margin in 2025?
In 2025, Surrozen, Inc.'s operating margin was -1,210.58%, compared with -239.69% in 2024.
How has Surrozen, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Surrozen, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2025 (-1,210.58%).
How does Surrozen, Inc.'s operating margin compare with similar companies?
Surrozen, Inc.'s operating margin (-385.28%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.